Clinical trialObsUnknown
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
- Outcome
- Outcome unknown
- Phase
- Obs
- Status
- Unknown
- Study type
- Observational
- Start
- 1 January 2020
- Expected end
- 31 December 2023
- Enrollment
- 400 participants
- Sites
- 1
- Primary outcomes
- Overall Survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 February 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 4
- BackgroundRadiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. DOI 10.1016/j.prro.2019.06.016↗
- BackgroundAdjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-I… DOI 10.1002/cam4.1967↗
- BackgroundAdjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-… DOI 10.1016/s0140-6736(16)30583-9↗
- BackgroundCapecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study. PMID 26637914↗